Skip to main content
AZTAAzenta, Inc.Sell5.2·$44.80
SellModerate Confidence
Investment thesis

Azenta has positive momentum and a fresh earnings beat, but the price of $45.65 is already above the $39.85 analyst target and quality is below the minimum bar, leaving little upside.

Thesis pillars

  • Quality Below Minimum→Stable
  • Price Above Analyst Target↑Improving
  • Breakout Momentum↓Deteriorating
  • +2 more pillars — see the Why tab for full reasoning

Pillars as of Nov 14, 2026, based on the 10-K filed Dec 4, 2025

Full reasoning →

Open full analysis

Azenta, Inc. (AZTA) Stock Analysis

Breakout setup

SellValueGrowthModerate Confidence

Healthcare · Medical Instruments & Supplies

Sell if holding. Engine safety override at $44.80: Quality below floor (3.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10. Specifically: High short interest: 22%; Below-average business quality.

Azenta is a global provider of biological and chemical sample exploration and management solutions for the life sciences industry, operating through two segments: Sample Management Solutions (automated cold-chain storage, cryogenic systems, sample repository services) and... Read more

$44.80+2.1% A.UpsideScore 5.2/10#18 of 29 Medical Instruments & Supplies
QualityF-score8 / 9FCF yield5.18%
Stop $41.66Analyst target $45.76(−13% haircut)A.R:R 0.1:1
Analyst consensus$52.60+17.4%5 analysts with price targets
$45.76Analyst target
$44.80price
$52.60mean
$57

Sell if holding. Engine safety override at $44.80: Quality below floor (3.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10. Specifically: High short interest: 22%; Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 63, MACD bullish. Score 5.2/10, moderate confidence.

Passes 6/9 gates (positive momentum, clean insider activity, news events none recent, earnings proximity 73d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.

10-K grounded · weekly refresh

About Azenta, Inc.

About Azenta, Inc.

Azenta serves approximately 14,000 customers in roughly 95 countries through two segments, Sample Management Solutions and Multiomics, operating a network of 14 genomic-services laboratories (seven in the United States, three in China, two in the United Kingdom, and one each in Japan and Germany) alongside automated cold-chain storage systems that hold samples from ambient temperatures down to -190°C. The company divested its founding semiconductor automation business for $2.9 billion in February 2022 and is now pursuing the sale of its B Medical Systems refrigeration unit to concentrate on its two remaining life-sciences segments.

Azenta's Sample Management Solutions segment earns revenue from Sample Repository Services (on-site and off-site cold-chain storage, logistics, and informatics) and Core Products such as automated stores, cryogenic freezers, sample tubes, and consumables, sold mostly through a direct sales force supplemented by distributors for consumables and emerging markets. The Multiomics segment sells gene sequencing, gene synthesis, and bioinformatics services, competing against BGI Genomics, Eurofins, GenScript, Integrated DNA Technologies, Novogene, and Twist Bioscience, while Sample Management Solutions competes with Hamilton Company, Liconic, Laboratory Corporation of America, and Thermo Fisher Scientific. Manufacturing is concentrated at two major facilities, in Missouri and in Manchester and Wotton, United Kingdom, and the company held approximately $119.6 million of cash denominated in foreign currency as of September 30, 2025, a substantial share of its total cash position.

Show full overview

Azenta's genomic-services footprint carries geopolitical exposure through China: three of its 14 genomic laboratories and one of its sample-storage sites are located in Beijing and other Chinese locations, and the 10-K specifically flags the risk of lost revenue and damaged customer relationships in China from escalating U.S.-China trade tensions and tariffs, on top of broader supply-chain risk from reliance on single-source suppliers. Azenta also disclosed in April 2026 that Ginger Zhou departed as President of its Multiomics segment, with Maravai LifeSciences' former CEO William Martin installed as her successor the same day, a leadership change in the segment most exposed to the China-sourcing and trade-policy risks described above.

See also: Healthcare · Medical Instruments & Supplies

From Azenta, Inc.'s most recent 10-K filing, extracted July 6, 2026.

news + 30-day 8-K events · 5-min refresh

Recent developments

updated Nov 17, 2026

Recent Developments — Azenta, Inc.

Latest item Nov 17, 2026 · Generated 2026-11-22T11:57:08Z.

TrendMatrix Research · upcoming catalyst calendar

Upcoming dated catalysts

Wed, Feb 3, 202773d to earnings· next earnings call

Thesis

Rewards
No bull case signals
Risks
Target reached (2.1% upside)
Quality below floor (3.8 < 4.0)

Key Metrics

P/E (TTM)—
P/E (Fwd)50.3
Mkt Cap$1.9B
EV/EBITDA44.6
Profit Mgn-26.9%
ROE-10.1%
Rev Growth5.0%
Beta1.47
DividendNone
Analysts with ratings12

Quality Signals

Piotroski F8/9

Options Flow

P/C0.49bullish
IV70%elevated

Material Events(8-K, last 90d)

  • 2026-04-07Item 5.02MEDIUM
    Ginger Zhou stepped down as President of the Multiomics business effective April 6, 2026, with no disagreement with the company cited; she continues as a consultant through November 2026. William 'Trey' Martin III, former CEO of Maravai LifeSciences, was appointed as her successor effective the same day.
    SEC filing →

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Rating Breakdown

1 floor-breaker

Unprofitable operations — net margin -26.9%. Quality floor flags this regardless of sector context.static

Roe
0.0
Roa
0.0
Operating Margin
0.0
Net Margin
0.0
Gross Margin
4.8
Moat
5.4
Fcf Quality
6.0
Piotroski F
8.9
Current Ratio
9.0
FCF-positive but moderate margins (FCF margin 16%, FCF yield 5.2%)No competitive moatStrong Piotroski F-Score: 8/9
GatesA.R:R 0.1 < 1.5@spotMomentum 5.1<5.5 (soft — BUY_NOW allowed but watch)Executive change: officer departure/appointmentMomentum 5.1>=4.5Insider activity: OKNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 73d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARBreakoutSuitability: Aggressive
RSI
63 · Neutral
↑ 20D MA↑ 50D MA↑ 200D MAGOLDEN CROSSSupport $35.05Resistance $50.05

Price Targets

$42
$46
A.Upside+2.1%
A.R:R0.1:1

Position Sizing

ConvictionNone
Suggested %0%
Max %0%
RegimeSteady

Risk Alerts

! Target reached (2.1% upside)
! Quality below floor (3.8 < 4.0)
! asymmetry at 0.1 (below the engine's 1.5 threshold)@spot

Earnings

B
B
M
M
2/4 beats
Next Earnings2027-02-03 (73d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is AZTA stock a buy right now?

Sell if holding. Engine safety override at $44.80: Quality below floor (3.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10. Specifically: High short interest: 22%; Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 63, MACD bullish. Prior stop was $41.66. Score 5.2/10, moderate confidence.

What is the AZTA stock price target?

Analyst target: $45.76 (+2.1% upside). Prior stop was $41.66. Stop-loss: $41.66.

What are the risks of investing in AZTA?

Target reached (2.1% upside); Quality below floor (3.8 < 4.0).

Is AZTA overvalued or undervalued?

Azenta, Inc. trades at a P/E of N/A (forward 50.3). TrendMatrix value score: 5.1/10. Verdict: Sell.

What do analysts say about AZTA?

12 analysts rate AZTA, with a consensus score of 3.9/5. 5 analysts publish price targets averaging $53.

What does Azenta, Inc. do?Azenta is a global provider of biological and chemical sample exploration and management solutions for the life...

Azenta is a global provider of biological and chemical sample exploration and management solutions for the life sciences industry, operating through two segments: Sample Management Solutions (automated cold-chain storage, cryogenic systems, sample repository services) and Multiomics (gene sequencing and synthesis services). The company serves approximately 14,000 customers across roughly 95 countries and is pursuing the sale of its B Medical Systems refrigeration business to sharpen its focus on those two core segments.

Related stocks: MMED (MiniMed Group, Inc.) · ALGN (Align Technology, Inc.) · ATRC (AtriCure, Inc.) · MMSI (Merit Medical Systems, Inc.) · AVTR (Avantor, Inc.)
Home › Stocks › AZTA

Latest news

Latest News

Fiscal.ai5d ago
Fiscal.ai10d agoLegal
Fiscal.ai10d agoAnalyst
Benzinga11d agoAnalyst
Fiscal.ai12d ago
Benzinga12d agoEarnings
Benzinga12d ago
Fiscal.ai23d ago
Benzinga23d agoMerger Acquisition
Fiscal.ai25d agoEarnings
Fiscal.ai26d ago
Benzinga47d agoEarnings
Benzinga51d ago
Benzinga79d ago
Benzinga90d ago
Benzinga90d agoLeadership Change
Benzinga108d ago
Benzinga109d agoAnalyst
Benzinga110d agoEarnings
Benzinga110d ago